Epidemiology Immunotherapy Targeted Therapies Biomarkers Clinical Trials Drug Development Clinical Studies Innovative Therapies Treatment Options Genetic Mutations Tumor Immunology GTPase Mutations Therapeutics Young Adults Anti-Cancer Strategies DNA Repair in Cancer Alcohol Studies Diet and Cancer Cell Therapy Radiation Oncology Survivorship Studies Tumor Microenvironment Clonal Haematopoiesis Charitable Organizations Patient Care Prostate Cancer Research Bladder Cancer Tumor Genetics Cellular Mechanisms Dietary Patterns Chromosomal Imbalances Innovative Treatments Treatment Efficacy Artificial Intelligence Virotherapy Environmental Factors Funding Treatment Advances Genetic Research Cancer Causes Therapeutic Development Genetic Testing Brain Cancer Industry Impact Patient Involvement Tobacco Use Gynecologic Cancers Drug Licensing Gene Therapy IARC Therapeutic Approaches Investment Hallmarks of Cancer Comparative Oncology Alcohol and Cancer Young Adult Cancer Metastasis Melanoma Research Solid Tumors Patient Experiences Scientific Leadership Diagnostic Tests Diabetes Medications Tumor Biology
Want to see what podcasts are saying about this topic? Search across 140K+ podcasts. Explore Radar
Backed by a $650 million up-front payment, the agreement places Pfizer in charge of global development for a 12-program cancer portfolio discovered and advanced by Innovent.
